Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma?

Agostino Chiaravalloti, Marco Pagani, Barbara Di Pietro, Roberta Danieli, Mario Tavolozza, Laura Travascio, Cristiana R. Caracciolo, Giovanni Simonetti, Maria Cantonetti, Orazio Schillaci

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

OBJECTIVE: The aim of the study was to investigate the effect of chemotherapy treatment with ABVD on brain glucose metabolism in patients with Hodgkin's disease (HD). METHODS: A total of 49 patients (23 men, 26 women; mean age 32±9 years) diagnosed with HD were included in the study. All of them underwent a baseline (PET0) and an interim (PET2) 2-deoxy-2-[F]fluoro-D-glucose (18F-FDG) PET/computed tomography (CT) brain scan. All patients were treated after PET0 with two cycles of ABVD consisting of doxorubicin (adriamycin), bleomycin, vinblastine, and dacarbazine for 2 months. Thirty-five patients were evaluated further 15±6 days after four additional cycles (PET6). Differences in brain 18F-FDG uptake were analyzed by statistical parametric mapping (SPM2). RESULTS: Compared with PET0, PET2 showed a significantly higher metabolic activity in the right angular gyrus (Brodmann area 39) and a significant metabolic reduction in Brodmann areas 10, 11, and 32 bilaterally. All these changes disappeared at PET6. CONCLUSION: Our results support the conclusion of a very limited impact of ABVD chemotherapy on brain metabolism in patients with HD.

Original languageEnglish
Pages (from-to)57-63
Number of pages7
JournalNuclear Medicine Communications
Volume34
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Hodgkin Disease
Fluorodeoxyglucose F18
Glucose
Drug Therapy
Brain
Doxorubicin
Dacarbazine
Parietal Lobe
Vinblastine
Bleomycin
Tomography
Therapeutics

Keywords

  • ABVD
  • Chemobrain
  • Chemotherapy
  • Depression
  • Hodgkin's disease
  • Post-traumatic stress disorder

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Chiaravalloti, A., Pagani, M., Di Pietro, B., Danieli, R., Tavolozza, M., Travascio, L., ... Schillaci, O. (2013). Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma? Nuclear Medicine Communications, 34(1), 57-63. https://doi.org/10.1097/MNM.0b013e32835aa7de

Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma? / Chiaravalloti, Agostino; Pagani, Marco; Di Pietro, Barbara; Danieli, Roberta; Tavolozza, Mario; Travascio, Laura; Caracciolo, Cristiana R.; Simonetti, Giovanni; Cantonetti, Maria; Schillaci, Orazio.

In: Nuclear Medicine Communications, Vol. 34, No. 1, 01.2013, p. 57-63.

Research output: Contribution to journalArticle

Chiaravalloti, A, Pagani, M, Di Pietro, B, Danieli, R, Tavolozza, M, Travascio, L, Caracciolo, CR, Simonetti, G, Cantonetti, M & Schillaci, O 2013, 'Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma?', Nuclear Medicine Communications, vol. 34, no. 1, pp. 57-63. https://doi.org/10.1097/MNM.0b013e32835aa7de
Chiaravalloti, Agostino ; Pagani, Marco ; Di Pietro, Barbara ; Danieli, Roberta ; Tavolozza, Mario ; Travascio, Laura ; Caracciolo, Cristiana R. ; Simonetti, Giovanni ; Cantonetti, Maria ; Schillaci, Orazio. / Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma?. In: Nuclear Medicine Communications. 2013 ; Vol. 34, No. 1. pp. 57-63.
@article{ca87eaf7d3e542319d0338c4b2637bc6,
title = "Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma?",
abstract = "OBJECTIVE: The aim of the study was to investigate the effect of chemotherapy treatment with ABVD on brain glucose metabolism in patients with Hodgkin's disease (HD). METHODS: A total of 49 patients (23 men, 26 women; mean age 32±9 years) diagnosed with HD were included in the study. All of them underwent a baseline (PET0) and an interim (PET2) 2-deoxy-2-[F]fluoro-D-glucose (18F-FDG) PET/computed tomography (CT) brain scan. All patients were treated after PET0 with two cycles of ABVD consisting of doxorubicin (adriamycin), bleomycin, vinblastine, and dacarbazine for 2 months. Thirty-five patients were evaluated further 15±6 days after four additional cycles (PET6). Differences in brain 18F-FDG uptake were analyzed by statistical parametric mapping (SPM2). RESULTS: Compared with PET0, PET2 showed a significantly higher metabolic activity in the right angular gyrus (Brodmann area 39) and a significant metabolic reduction in Brodmann areas 10, 11, and 32 bilaterally. All these changes disappeared at PET6. CONCLUSION: Our results support the conclusion of a very limited impact of ABVD chemotherapy on brain metabolism in patients with HD.",
keywords = "ABVD, Chemobrain, Chemotherapy, Depression, Hodgkin's disease, Post-traumatic stress disorder",
author = "Agostino Chiaravalloti and Marco Pagani and {Di Pietro}, Barbara and Roberta Danieli and Mario Tavolozza and Laura Travascio and Caracciolo, {Cristiana R.} and Giovanni Simonetti and Maria Cantonetti and Orazio Schillaci",
year = "2013",
month = "1",
doi = "10.1097/MNM.0b013e32835aa7de",
language = "English",
volume = "34",
pages = "57--63",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma?

AU - Chiaravalloti, Agostino

AU - Pagani, Marco

AU - Di Pietro, Barbara

AU - Danieli, Roberta

AU - Tavolozza, Mario

AU - Travascio, Laura

AU - Caracciolo, Cristiana R.

AU - Simonetti, Giovanni

AU - Cantonetti, Maria

AU - Schillaci, Orazio

PY - 2013/1

Y1 - 2013/1

N2 - OBJECTIVE: The aim of the study was to investigate the effect of chemotherapy treatment with ABVD on brain glucose metabolism in patients with Hodgkin's disease (HD). METHODS: A total of 49 patients (23 men, 26 women; mean age 32±9 years) diagnosed with HD were included in the study. All of them underwent a baseline (PET0) and an interim (PET2) 2-deoxy-2-[F]fluoro-D-glucose (18F-FDG) PET/computed tomography (CT) brain scan. All patients were treated after PET0 with two cycles of ABVD consisting of doxorubicin (adriamycin), bleomycin, vinblastine, and dacarbazine for 2 months. Thirty-five patients were evaluated further 15±6 days after four additional cycles (PET6). Differences in brain 18F-FDG uptake were analyzed by statistical parametric mapping (SPM2). RESULTS: Compared with PET0, PET2 showed a significantly higher metabolic activity in the right angular gyrus (Brodmann area 39) and a significant metabolic reduction in Brodmann areas 10, 11, and 32 bilaterally. All these changes disappeared at PET6. CONCLUSION: Our results support the conclusion of a very limited impact of ABVD chemotherapy on brain metabolism in patients with HD.

AB - OBJECTIVE: The aim of the study was to investigate the effect of chemotherapy treatment with ABVD on brain glucose metabolism in patients with Hodgkin's disease (HD). METHODS: A total of 49 patients (23 men, 26 women; mean age 32±9 years) diagnosed with HD were included in the study. All of them underwent a baseline (PET0) and an interim (PET2) 2-deoxy-2-[F]fluoro-D-glucose (18F-FDG) PET/computed tomography (CT) brain scan. All patients were treated after PET0 with two cycles of ABVD consisting of doxorubicin (adriamycin), bleomycin, vinblastine, and dacarbazine for 2 months. Thirty-five patients were evaluated further 15±6 days after four additional cycles (PET6). Differences in brain 18F-FDG uptake were analyzed by statistical parametric mapping (SPM2). RESULTS: Compared with PET0, PET2 showed a significantly higher metabolic activity in the right angular gyrus (Brodmann area 39) and a significant metabolic reduction in Brodmann areas 10, 11, and 32 bilaterally. All these changes disappeared at PET6. CONCLUSION: Our results support the conclusion of a very limited impact of ABVD chemotherapy on brain metabolism in patients with HD.

KW - ABVD

KW - Chemobrain

KW - Chemotherapy

KW - Depression

KW - Hodgkin's disease

KW - Post-traumatic stress disorder

UR - http://www.scopus.com/inward/record.url?scp=84870874325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870874325&partnerID=8YFLogxK

U2 - 10.1097/MNM.0b013e32835aa7de

DO - 10.1097/MNM.0b013e32835aa7de

M3 - Article

VL - 34

SP - 57

EP - 63

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 1

ER -